Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Non-Small-Cell Lung 10 Neoplasms 4 Neoplasm Metastasis 3 Lung Neoplasms 2 Gastrointestinal Neoplasms 2 Colorectal Neoplasms 2 Breast Neoplasms 2 Urinary Bladder Neoplasms 1 Thyroid Neoplasms 1 Thyroid Cancer, Papillary 1 Thoracic Neoplasms 1 Solid Tumors 1 Sarcoma 1 Salivary Gland Neoplasms 1 Respiratory Tract Neoplasms 1 Respiratory Tract Diseases 1 Rare Tumour 1 Rare Tumor 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neuroendocrine Tumors 1 Neoplasms, Unknown Primary 1 Neoplasms by Site 1 Melanoma 1 Lymphoma, Large-Cell, Anaplastic 1 Intestinal Neoplasms 1 Intestinal Diseases 1 Hematologic Neoplasms 1 Head and Neck Neoplasms 1 Genomic Instability 1

Interventions

Gemcitabine 9 Carboplatin 8 Paclitaxel 6 Capecitabine 4 Bevacizumab 4 pembrolizumab 3 Irinotecan 3 Erlotinib Hydrochloride 3 atezolizumab 2 Peripheral Blood Stem Cell Transplantation 2 Oxaliplatin 2 Filgrastim 2 Cisplatin 2 CP protocol 2 tislelizumab 1 tegafur-gimeracil-oteracil 1 spartalizumab 1 sintilimab 1 pertuzumab 1 pemigatinib 1 olaparib 1 ivosidenib 1 ipatasertib 1 etoposide phosphate 1 entrectinib 1 cobimetinib 1 belinostat 1 antineoplaston AS 2-1 1 antineoplaston A10 1 alectinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Neoplasms, Unknown Primary × alectinib × Clear all

NCT03498521 2025-11-19

CUPISCO

Hoffmann-La Roche

Phase 2 Completed

529 enrolled 16 charts

Neoplasms, Unknown Primary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡